Compare Stocks: SER, NMRA, CRDL, and SIGA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$2.20 +1.9%	$1.46	$0.88 ▼ $2.28	$255.59M	0.79	1.63 million shs	1.07 million shs
NMRA Neumora Therapeutics	$1.31 -3.0%	$1.59	$0.83 ▼ $3.65	$246.14M	2.71	705,403 shs	546,973 shs
SER Serina Therapeutics	$2.73 +1.5%	$2.32	$1.22 ▼ $5.83	$69.34M	1.18	61,524 shs	14,940 shs
SIGA Siga Technologies	$3.29 +1.9%	$3.28	$2.83 ▼ $9.45	$236.39M	0.97	738,111 shs	899,421 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	0.00%	+13.40%	+61.76%	+98.20%	+101.83%
NMRA Neumora Therapeutics	0.00%	-5.76%	-20.12%	-19.63%	-25.14%
SER Serina Therapeutics	0.00%	+10.98%	+16.17%	+45.21%	+272,999,900.00%
SIGA Siga Technologies	0.00%	+7.52%	+5.45%	-23.49%	-61.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$2.20 +1.9%	$1.46	$0.88 ▼ $2.28	$255.59M	0.79	1.63 million shs	1.07 million shs
NMRA Neumora Therapeutics	$1.31 -3.0%	$1.59	$0.83 ▼ $3.65	$246.14M	2.71	705,403 shs	546,973 shs
SER Serina Therapeutics	$2.73 +1.5%	$2.32	$1.22 ▼ $5.83	$69.34M	1.18	61,524 shs	14,940 shs
SIGA Siga Technologies	$3.29 +1.9%	$3.28	$2.83 ▼ $9.45	$236.39M	0.97	738,111 shs	899,421 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	0.00%	+13.40%	+61.76%	+98.20%	+101.83%
NMRA Neumora Therapeutics	0.00%	-5.76%	-20.12%	-19.63%	-25.14%
SER Serina Therapeutics	0.00%	+10.98%	+16.17%	+45.21%	+272,999,900.00%
SIGA Siga Technologies	0.00%	+7.52%	+5.45%	-23.49%	-61.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	354.55% Upside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	401.64% Upside
SER Serina Therapeutics	3.00	Buy	$8.00	193.04% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SER, NMRA, CRDL, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	NMRA Neumora Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
7/1/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.24 per share	N/A
SER Serina Therapeutics	$130K	533.40	N/A	N/A	$0.74 per share	3.69
SIGA Siga Technologies	$94.57M	2.50	$0.33 per share	9.88	$2.30 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
SER Serina Therapeutics	-$19.18M	N/A	N/A	N/A	N/A	N/A	-416.40%	-132.69%	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)

Latest SER, NMRA, CRDL, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/13/2026	Q2 2026	SER Serina Therapeutics	N/A	-$0.55	N/A	-$0.55	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
SER Serina Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	N/A	5.55	5.55
NMRA Neumora Therapeutics	1.19	4.50	4.50
SER Serina Therapeutics	0.16	6.65	6.65
SIGA Siga Technologies	N/A	21.72	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
NMRA Neumora Therapeutics	47.65%
SER Serina Therapeutics	12.50%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
NMRA Neumora Therapeutics	26.94%
SER Serina Therapeutics	17.70%
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	116.18 million	110.08 million	Not Optionable
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable
SER Serina Therapeutics	N/A	25.40 million	20.90 million	N/A
SIGA Siga Technologies	40	71.85 million	69.89 million	Optionable

SER, NMRA, CRDL, and SIGA Headlines

Recent News About These Companies

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

3 hours ago | insidermonkey.com

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

September 4 at 3:28 AM | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Shares Up 2.6% - Should You Buy?

August 31, 2026 | marketbeat.com

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor 10 Jahren verdient

August 31, 2026 | finanzen.netF

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Siga Technologies Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

SIGA Technologies 2026年第二季度每股收益$0.17，盘后股价小幅上涨

August 6, 2026 | cn.investing.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

August 6, 2026 | markets.businessinsider.com

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026 | globenewswire.com

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

July 28, 2026 | seekingalpha.com

Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?

June 30, 2026 | finance.yahoo.com

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

May 22, 2026 | finance.yahoo.com

SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed

May 15, 2026 | finance.yahoo.com

Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings

May 14, 2026 | finance.yahoo.com

SIGA (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | fool.com

SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months

May 8, 2026 | msn.com

SIGA Technologies, Inc. Q1 2026 Earnings Call Summary

May 8, 2026 | finance.yahoo.com

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026 | globenewswire.com

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

April 30, 2026 | globenewswire.com

Why SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%

March 28, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SER, NMRA, CRDL, and SIGA Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$2.20 +0.04 (+1.85%)

As of 09/4/2026 04:00 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Neumora Therapeutics NASDAQ:NMRA

$1.31 -0.04 (-2.96%)

As of 09/4/2026 04:00 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Serina Therapeutics NYSEAMERICAN:SER

$2.73 +0.04 (+1.49%)

As of 09/4/2026 04:10 PM Eastern

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Siga Technologies NASDAQ:SIGA

$3.29 +0.06 (+1.86%)

As of 09/4/2026 04:00 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SER, NMRA, CRDL, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SER, NMRA, CRDL, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SER, NMRA, CRDL, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SER, NMRA, CRDL, and SIGA Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Neumora Therapeutics NASDAQ:NMRA

Serina Therapeutics NYSEAMERICAN:SER

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SER, NMRA, CRDL, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SER, NMRA, CRDL, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SER, NMRA, CRDL, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SER, NMRA, CRDL, and SIGA Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Neumora Therapeutics NASDAQ:NMRA

Serina Therapeutics NYSEAMERICAN:SER

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools